Front. Med. Frontiers in Medicine Front. Med. 2296-858X Frontiers Media S.A. 10.3389/fmed.2026.1789363 Correction Correction: Factors influencing therapeutic efficacy of non-lactational mastitis based on hematological inflammatory markers and establishment of a predictive model Peng Jinjuan 1 Li Li 1 Fan Lili 1 Lu Qun 2 * Department of Breast Surgery, The Fourth People's Hospital of Zhenjiang, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China Department of Breast Surgery, Changzhou Maternal and Child Health Care Hospital, Changzhou, China Correspondence: Qun Lu, luuqun@126.com 20 02 2026 2026 13 1789363 16 01 2026 02 02 2026 Copyright © 2026 Peng, Li, Fan and Lu. 2026 Peng, Li, Fan and Lu https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Factors influencing therapeutic efficacy of non-lactational mastitis based on hematological inflammatory markers and establishment of a predictive model by Peng, J., Li, L., Fan, L., and Lu, Q. (2026). Front. Med. 12:1668664. doi: 10.3389/fmed.2025.1668664 inflammatory markers non-lactational mastitis mastitis SII CRP section-at-acceptance Translational Medicine

Affiliation “Department of Breast Surgery, The Fourth People's Hospital of Zhenjiang, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China” was erroneously given as “Department of Breast Surgery, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.”

There was a mistake in Table 2 as published. There were data errors and missing values in the Good efficacy group (n = 133) column in Table 2.

The corrected Table 2 appears below.

Univariate analysis of factors influencing therapeutic efficiency of NLM.

Baseline data Poor efficacy group (n = 52) Good efficacy group (n = 133) t/χ2 Value p-Value
Age (years) 35.96 ± 5.46 35.23 ± 5.40 0.824 0.411
Number of pregnancies < 2 31 (59.62) 75 (56.39) 0.159 0.690
≥2 21 (40.38) 58 (43.61)
Menstrual disorders Yes 33 (63.46) 85 (63.91) 0.003 0.955
No 19 (36.54) 48 (36.09)
Overweight/obesity Yes 22 (42.31) 36 (27.07) 4.034 0.045
No 30 (57.69) 97 (72.93)
History of lactational mastitis Yes 16 (30.77) 43 (32.33) 0.042 0.838
No 36 (69.23) 90 (67.67)
History of hyperprolactinemia Yes 15 (28.85) 40 (30.08) 0.027 0.869
No 37 (71.15) 93 (69.92)
History of breast trauma Yes 11 (21.15) 24 (18.05) 0.236 0.628
No 41 (78.85) 109 (81.95)
Abscess formation Yes 40 (76.92) 101 (75.94) 0.020 0.888
No 12 (23.08) 32 (24.06)
Sinus tract formation Yes 10 (19.23) 21 (15.79) 0.317 0.573
No 42 (80.77) 112 (84.21)
History of hormone therapy Yes 6 (11.54) 11 (8.27) 0.478 0.489
No 46 (88.46) 122 (91.73)
SII 200.01 ± 23.30 130.32 ± 27.79 16.010 < 0.001
PCT (ng/L) 0.60 ± 0.04 0.59 ± 0.05 1.289 0.199
CRP (mg/L) 26.95 ± 2.04 21.81 ± 4.07 8.680 < 0.001

IL-8, interleukin-8; PCT, procalcitonin; IL-6, interleukin-6; CRP, C-reactive protein.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited and reviewed by: Muneeb A. Faiq, New York University, United States